Consequences of Verteporfin Photodynamic Therapy on Choroidal Neovascular Membranes

Tatar, Olcay; Kaiserling, E.; Adam, Annemarie; Gelişken, Faik; Shinoda, Kei; Völker, Michael; Lafaut, B. A.; Bartz‐Schmidt, Karl Ulrich; Grisanti, Salvatore

doi:10.1001/archopht.124.6.815

Cited by 37 publications

(35 citation statements)

References 27 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Фактор роста эндотелия сосудов, секретирую-щийся клетками ретинального пигментного эпи-телия, -один из важнейших регуляторов патоло-гического ангиогенеза при ВМД, особенно при влажной форме [33]. Высказываются предполо-жения о возможности влияния полиморфизма гена VEGF на развитие и течение заболевания, но данные многочисленных исследований в различ-ных популяциях не однородны.…”

Section: Discussionunclassified

NETWORK APPROACH TO ANALYSIS OF QUANTITATIVE TRAIT LOCI FOR TUMOR NECROSIS FACTOR (TNFα-863, TNFα-308, TNFα-238), VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF-2578, VEGF+936) AND MATRIX METALLOPROTEINASE (Ммр2-1306, Ммр3-1171, Ммр9-1569) GENES IN AGERELATED MACULAR DEGENERATION

Shevchenko¹,

Prokofyev²,

Vi³

et al. 2017

Med. immunol.

View full text Add to dashboard Cite

Section: Discussionunclassified

NETWORK APPROACH TO ANALYSIS OF QUANTITATIVE TRAIT LOCI FOR TUMOR NECROSIS FACTOR (TNFα-863, TNFα-308, TNFα-238), VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF-2578, VEGF+936) AND MATRIX METALLOPROTEINASE (Ммр2-1306, Ммр3-1171, Ммр9-1569) GENES IN AGERELATED MACULAR DEGENERATION

Shevchenko¹,

Prokofyev²,

Vi³

et al. 2017

Med. immunol.

View full text Add to dashboard Cite

“…[16][17][18] ItisknownthatPDTincre a sestheVEGFle velsinCNVM. 19,20 Ra ni bi zumab and be va ci zu mab in hi bit all iso forms of vas cu laren dot he li algrowthfac tor. 10,11,[16][17][18] Ho wever,pe gap ta nibisanap ta me ricmo le cu lewhichinhi bitsonlythe165iso formofVEGF.…”

Section: Discussionmentioning

confidence: 99%

Pegaptanib Versus Combined Pegaptanib and Photodynamic Therapy for Neovascular Age-Related Macular Degeneration

Akduman¹,

Kaderli²,

Kim³

et al. 2010

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

ABS TRACTOb jec ti ve: Theaimofthisstudyistore vi ewourex pe ri en cewithPe gap ta nibinpa tientswithne o vas cu larage-re la tedma cu larde ge ne ra ti on(AMD)andtode ter mi newhet herout comeswo uldbeim pro vedbycom bi ningPe gap ta nibwithpho tody na micthe rapy(PDT).Ma te ri al andMet hods:Ins ti tu ti o nal,ret ros pec ti veca sese ri es.Thechartsof20pa ti entswithne o vas cu lar AMDwhore ce i vedPe gap ta nibmo not he rapyorcom bi nedocu larPDTwithVer te por finwe reretros pec ti velyre vi e wed.Ma inout co meme a su rescon sis tedofthenum beroftre at mentsapp li ed, Snel lenbest-cor rec tedvi su alacu ity(BCVA),an gi og rap hicle si oncha rac te ris ticsandcen terfi eld thick ness(CFT)inop ti calco he ren ceto mog raphy(OCT).Re sults:Ave ra gefol low-upti mewas7.7 months(ran ge,3-12months).Tenpa ti ents(50%)we reinPe gap ta nibmo not he rapygro up(Gro up A)and10pa ti entswe reincom bi na ti onthe rapywithPDTgro up(Gro upB).Pa ti entsinbothgroupsre ce i ved2to9(me an,5.2)Pe gap ta nibin jec ti ons.Gro upBre ce i ved1to4(me an,1.8)PDTtreat ments.Ini ti alBCVAran gedfrom20/50to20/3200(me an,20/509),fi nalBCVAran gedfrom20/70 to20/3200(me an,20/759).Ingro upA,theme anini ti alandfi nalBCVAwe re20/650and20/617, res pec ti vely(p=0.590).Thecor res pon dingnum bersingro upBwe re20/398and20/1060,res pecti vely(p=0.062).Fo urofthe10eyes(40%)inGro upBlostthreeli nesormo re.No neoftheeyes inGro upAlostthreeli nesormo revi si on(p=0.087).The rewasne it hersig ni fi cantchan geinthe le si onsi ze(p=0.513),norinCFT(315µmto268µm,p=0.99).Conc lu si on:There sultsofthisstudy sug gestthatcom bi nedocu larPDTandPe gap ta nibtre at mentmaynotbesu pe ri ortoPe gap ta nibaloneinpa ti entswithne o vas cu larAMD.Furt herstu di esarene e ded.KeyWords:Cho ro i dalne o vas cu la ri za ti on;pe gap ta nib;ver te por fin ÖZETAmaç:Buça lış ma dane o vas kü leryaşbağımlımakülerdejenerasyon(YBMD)ol gu la rın dauygu la dı ğı mızPe gap ta nibte da vi si ninso nuç la rı nıvekom bi nePe gap ta nibvefotodinamiktedavinin (FDT)olum luet ki si ninolupol ma dı ğı nınaraş tı rıl ma sıamaç lan dı.Ge reçveYön tem ler:Ret ros pektifol guse ri si.Ne o vas kü lerYBMDne de niy letekba şı nave yaFDTilekom bi nePe gap ta nibte da vi siuygu la nan20ol gu nunka yıt la rıret ros pek tifola rakin ce len di.Anaiz lempa ra met re le riola rakuy gu la nan te da visa yı sı,Snel leneniyidü zel til mişgör mekes kin li ği(EİDGK),an ji yog ra fiklez yonözel lik le rive op tikko he rensto mog ra fi desan tralma ku laka lın lı ğı(SMK)de ğer len di ril di.Bul gu lar: Or ta la maizlemsü re si7.7ay dı(3-12ay).Onol gu ya(%50)tekba şı naPe gap ta nib(GrupA)ve10ol gu yadaFDT ilekom bi nete da vi(GrupB)uy gu lan dı.Herikigrup tauy gu la nanPe gap ta niben jek si yonsa yı sı2ile 9ara sın dade ğiş mek tey di(or ta la ma5.2).GrupB'de kiol gu la ra1ile4kez(or ta la ma1.8)FDTuy gulan dı.Te da viön ce siEİDGK20/50ile20/3200ara sın day dı(or ta la ma20/509).Te da vison ra sıöl çü len sonEİDGKise20/70ile20/3200ar sın day dı(or ta la ma20/759).GrupA' dailkvesonEİDGKsı ra sıy -la20/65...

show abstract

“…[30][31][32] In .90% of the cases, however, a recurrence is seen within 3 months. [2][3][4][5][6] Enhanced VEGF expression 17 and predominance over pigment epithelium-derived factor 19 might contribute to this rebound effect. Herein, we investigated the potential involvement of Eselectin and endostatin in this process.…”

Section: Discussionmentioning

confidence: 99%

“…[26][27][28][29] Immunohistochemical analysis for VEGF and endostatin was performed by the alkaline-phosphatase method as described previously, 17 using an anti-human VEGF-A antibody (mouse, Mab, clone C-1; Santa Cruz Biotechnology, Santa Cruz, California) and an anti-human endostatin antibody (rabbit, polyclonal, Dianova GmbH, Hamburg). Haematoxylin (Chemmate, Code S2020, Dako) was used for counterstaining.…”

Section: Immunohistologymentioning

confidence: 99%

See 1 more Smart Citation

Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes

Tatar

Shinoda

Adam

et al. 2007

British Journal of Ophthalmology

View full text Add to dashboard Cite

Aim: To evaluate the effect of verteporfin photodynamic therapy (PDT) on endostatin with regard to expression of vascular endothelial growth factor (VEGF) in human choroidal neovascular membranes (CNVs) secondary to age-related macular degeneration. Methods: A retrospective review of an interventional case series of 68 patients who underwent removal of CNV. 29 patients were treated with PDT 3-655 days before surgery. 39 CNVs without previous treatment were used as controls. CNVs were stained for CD34, CD105, Ki-67, cytokeratin 18, endostatin, E-selectin and VEGF. ''Predominance score of VEGF over endostatin'' (mean) was defined as the difference between VEGF and endostatin staining scores. Results: In four CNVs treated by PDT 3 days previously, PS was significantly higher in the retinal pigment epithelium (mean = 2.5, p = 0.006) and stroma (mean = 2, p = 0.015) than in the control group (mean = 0). At longer post-PDT intervals, PS was significantly decreased in the retinal pigment epithelium (mean = 0, p = 0.019) and stroma (mean = 0, p = 0.015). Proliferative activity was high (p = 0.023), but mostly related to inflammatory cells. PDT did not influence E-selectin expression significantly. Conclusions: VEGF predominance over endostatin early after PDT might contribute to enhanced angiogenic activity associated with recurrences. Strategies upregulating or replacing endostatin early after PDT might increase the effectiveness of PDT. N eovascular age-related macular degeneration (AMD) is the leading cause of visual loss among elderly in the western world.

show abstract

Consequences of Verteporfin Photodynamic Therapy on Choroidal Neovascular Membranes

Cited by 37 publications

References 27 publications

NETWORK APPROACH TO ANALYSIS OF QUANTITATIVE TRAIT LOCI FOR TUMOR NECROSIS FACTOR (TNFα-863, TNFα-308, TNFα-238), VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF-2578, VEGF+936) AND MATRIX METALLOPROTEINASE (Ммр2-1306, Ммр3-1171, Ммр9-1569) GENES IN AGERELATED MACULAR DEGENERATION

NETWORK APPROACH TO ANALYSIS OF QUANTITATIVE TRAIT LOCI FOR TUMOR NECROSIS FACTOR (TNFα-863, TNFα-308, TNFα-238), VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF-2578, VEGF+936) AND MATRIX METALLOPROTEINASE (Ммр2-1306, Ммр3-1171, Ммр9-1569) GENES IN AGERELATED MACULAR DEGENERATION

Pegaptanib Versus Combined Pegaptanib and Photodynamic Therapy for Neovascular Age-Related Macular Degeneration

Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes

Contact Info

Product

Resources

About